Supernus Pharmaceuticals, Inc. (SUPN) stock trades up, “Buy” rating reaffirmed by Cantor Fitzgerald Analysts

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) shares rose on Friday January 13 on lower trade volume than normal after a number of analysts weighed in on the investing value of the stock and reiterated thier respective ratings.

Meanwhile, The Dow Jones Industrial Average DJIA, -0.03% slipped 5.27 points to close 19,885.73, moving in a roughly 100-point range all session. For the week, the blue-chip index is off 0.4%.

U.S. financial markets will be closed Monday for Martin Luther King Jr. Day.

The S&P 500 index SPX, +0.18% added 4.20 points, or 0.2%, to end at 2,274.64 for a weekly loss of 0.1%, and the Nasdaq Composite Index COMP, +0.48% climbed 26.63 points, or 0.5%, to finish at 5,574.12, its sixth all-time closing high in seven trading sessions.

Easy Guide to Investing in the Stock Market

Analysts at Cantor Fitzgerald reiterated a Buy rating on shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) in a reserach note to investors, making it one of the more closely watched stocks on Wall Street. With a rating of Buy on the stock, the company has a 52-week high of $27.50. The one-year price target of $29.67 is above the opening price of $24.95, resulting a number of other analysts to issue statements on the company in recent days. Stock prices sometimes get a bounce to the upside when analysts reiterate coverage.

Yesterday Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) shares last traded at $25.10, which represents a jump of $0.20 from the previous closing price. Opening at $24.95, they fluctuated from $24.85 and $25.44 throughout the day.

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) now has a market cap of 1.24B.

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) Average Daily Trading Volume

The stock’s average daily volume is 596,117 shares out of a total float 47,126,000 and some 349,279 shares crossed the trading desk yesterday, 82 percent below the average. lower than normal. Look for trading volume to pick up in the coming days as momentum traders often use increases in trading volume to identify heavy volume accumulation or distribution by institutional investors.

As with all potential breakouts, investors look for volume to be at least 40%-50% higher than normal on the breakout to show that fund managers and other professional investors are jumping in.

Institutional sponsorship just refers to ownership of a stock by mutual funds, banks, pension funds and other large institutions.

These professional investors have substantial teams of analysts researching thousands of stocks, so it is good validation to see them taking a postion in a stock you’re considering.

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

By spotting trends, moving averages allow investors to make those trends work in their favor and increase the number of successful trades.

With that in mind, Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) now has a 50-day MA of $23.78 and 200-day MA of $22.41. It has traded in a 52-week range between $9.51 – 27.50 and today’s last price is 8.73%% lower than the 52 week high of $27.50.

Earnings growth is a critical factor to look at when buying stocks and investors seek companies that have increased their earnings by at least 25% over a 3 year period.

DISCLOSURE: The views and opinions expressed in this article do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published. Required fields are marked *